1 Lung Cancer 2020: Epidemiology, etiology, and prevention
Bade BC, Dela Cruz CS. Clin Chest Med. 2020 Mar;41(1):1-24. doi: 10.1016/j.ccm.2019.10.001.PMID: 32008623
2. Molecular diagnostics and targeted therapies in non-small cell lung câncer (NSCLC): na update Sushma Jonna 1, Deepa S Subramaniam 1 Discov Med. 2019 Mar;27(148):167-170.
3.Expanding horizons for treatment of early-stage lung câncer Christine M Lovly 1
N Engl J Med. 2022 May 26;386(21):2050-2051. doi: 10.1056/NEJMe2203330.
4. Lung câncer treatment advances in 2022 Abu Rous F, Singhi EK, Sridhar A, Faisal MS, Desai A.Cancer Invest. 2023 Jan;41(1):12-24. doi: 10.1080/07357907.2022.2119479
5. The intenational association for the study of lung câncer staging Project: methods and guiding principles for the development of ninth edition TNMcalsification
6. Frank C Detterbeck 1, Katherine K Nishimura 2, Vanessa J Cilento 2, Meredith Giuliani 3, Mirella Marino 4, Raymond U Osarogiagbon 5, Ramon Rami-Porta 6, Valerie W Rusch 7, Hisao Asamura 8; International Association for the Study of Lung Cancer (IASLC) Staging and Prognostic Factors Committee and Advisory Boards
J Thorac Oncol. 2022 Jun;17(6):806-815. doi: 10.1016/j.jtho.2022.02.008.
7. Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives. Evgeny N Imyanitov 1, Aglaya G Iyevleva 2, Evgeny V Levchenko 3 Crit Rev Oncol Hematol. 2021 Jan;157:103194. doi: 10.1016/j.critrevonc.2020.103194.
8. Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer; Tatsuya Nagano*, Motoko Tachihara and Yoshihiro Nishimura Curr Cancer Drug Targets. 2019;19(8):595-630. doi: 10.2174/1568009619666181210114559
9;Nassim F, Sabath BF, Eapen GA , Lung Cancer Med Clin N Am 103 (2019) 463–473 https://doi.org/10.1016/j.mcna.2018.12.006 0025-7125/19/ª 2019
10. Nooredeen R, Bach H. Review Current and Future Development in Lung Cancer Diagnosis. Int. J. Mol. Sci. 2021, 22, 8661. https://doi.org/10.3390/ijms22168661
11 .US Preventive Services Task Force. Screening for Lung Cancer US Preventive Services Task Force Recommendation Statement .JAMA. 2021;325(10):962-970. doi:10.1001/jama.2021.1117
12. Oberndorfer F, Mu¨llauer L. Molecular pathology of lung cancer: current status and perspectives. Current Opin Oncol 2018 30(2)69-76
13 WHO Classification of tumours of the lung, pleura and Heart,2015, Lyon IARC.
J Thorac Oncol, 2015.
14 .Patel SA, Weiss J. Advances in the Treatment of Non–Small Cell Lung Cancer: Immunotherapy. Clin Chest Med 41 (2020) 237–247 https://doi.org/10.1016/j.ccm.2020.02.010 0272-5231/20/ 2020
15 .Hsu ML, MDa, Naidoo J. Principles of Immunotherapy in NonSmall Cell Lung Cancer. Thorac Surg Clin 30 (2020) 187–198 https://doi.org/10.1016/j.thorsurg.2020.01.009 1547-4127/20/ 2020
16Labarede O, a MOULAY A.Mezianeb MA. The Eighth Edition of TNM Staging of Lung Cancer: Reference Chart and Diagrams a Imaging Institute. TheOncologist 2018;23:844–848
17.Frank C. Detterbeck, Vanessa Bolejack, Douglas A. Arenberg John Crowley, Jessica S. Donington, Wilbur A. Franklin, Nicolas Girard, Edith M. Marom, Peter J. Mazzone, Andrew G. Nicholson, Valerie W. Rusch, Lynn T. Tanoue, William D. Travis, Hisao Asamura Ramón Rami-Porta, ,o on behalf of the IASLC Staging and Prognostic Factors Committee, Advisory Boards, Multiple Pulmonary Sites Workgroup, and Participating Institutions** The IASLC Lung Cancer Staging Project: Background Data and Proposals for the Classification of Lung Cancer with Separate Tumor Nodules in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer J Thorac Oncol 2016, 11: 681-692.
18.Tariq S, · So Yeon Kim SY, Novaes JMO, Cheng H. Update 2021: Management of Small Cell Lung Cancer (2021) 199:579–587 https://doi.org/10.1007/s00408-021-00486-y
19.Neoadjuvant immunotherapy in nonsmall cell lung cancer Georg Pall Curr Opin Oncol 2021, 33:59–63
20Wald O, Sugarbaker DJ. New concepts in treatment of malignant pleural mesothelioma. Ann Rev Med 2018, 69: 365-377.
Forma de Avaliação: Apresentação de trabalho científico publicado durante estágio.
Critérios de Aprovação: Mínimo nota 7,0
Frequência mínima 85%
Requisito para Ingresso:
Certificado de conclusão de Programa de Residência Médica, reconhecido pela Comissão Nacional de Residência Médica (CNRM), na área de Pneumologia
FORMA DE SELEÇÃO: Entrevista
